DiaMedica Announces Recently Granted Formulation Patent in U.S. for DM199
01 mai 2017 08h34 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - May 1, 2017) - DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF), today announced that the U.S. Patent...
DiaMedica Announces Dr. Nancy Chang to its Strategic Advisory Board
25 avr. 2017 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - April 25, 2017) - DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) is pleased to announce the addition of Dr. Nancy Chang...
DiaMedica Therapeutics Completes Private Placement With U.S. Based Family Office
18 avr. 2017 08h00 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - April 18, 2017) - DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF), a biopharmaceutical company focused on the development...
DiaMedica Announces Issuance of European Composition of Matter Patent and Additional Worldwide Filings for DM199
20 mars 2017 08h00 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - March 20, 2017) - DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF), today announced that the European Patent Office has...
DiaMedica Issues Stock Option Grant
17 mars 2017 17h00 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - March 17, 2017) - DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) today announces that the Board of Directors has granted...
DiaMedica Presents Updated Positive DM199 Phase Ib Trial Identifying A Superior Subcutaneous Delivery Profile
13 mars 2017 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - March 13, 2017) -
DM199 produced a superior drug profile
Identified optional dose of DM199 subcutaneous...
DiaMedica Announces Name Change to DiaMedica Therapeutics Inc.
23 déc. 2016 17h54 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 23, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) announced today it will change its name to DiaMedica Therapeutics...
DiaMedica Announces Positive Top-Line Results from DM199 Bridging Clinical Trial
20 déc. 2016 08h00 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 20, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF), a clinical stage biopharmaceutical company developing treatments for...
DiaMedica Expands its Business Development Capabilities
07 déc. 2016 08h00 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 7, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) announced today it has engaged Outreach 99 LLC ("Outreach") to assist...
DiaMedica Announces the Sale and Transfer of its DM-71 Product for Type 2 Diabetes
01 déc. 2016 08h00 HE
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 1, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) today announced the sale and transfer of its DM-71 product and related...